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Abstract
Multipotent adult progenitor cells (MAPC) are bone marrow-derived stem cells with a high 
growth rate suitable for therapeutical applications as three-dimensional (3D) aggregates. 
Combined applications of osteogenically differentiated MAPC (OD-MAPC) aggregates and 
adeno-associated viral vectors (AAV) in bone bioengineering are still deferred until information 
regarding expansion technologies, osteogenic potential, and AAV cytotoxicity and transduction 
efficiency is better understood. In this study, we tested whether self-complementary AAV 
(scAAV) can potentially be used as a gene delivery system in a OD-MAPC-based “in vivo” bone 
formation model in the craniofacial region. Both expansion of rat MAPC (rMAPC) and osteogenic 
differentiation with dexamethasone were also tested in 3D aggregate culture systems “in vitro” 
and “vivo”. Rat MAPCs (rMAPCs) grew as undifferentiated aggregates for 4 days with a 
population doubling time of 37h. After expansion, constant levels of Oct4 transcripts, and Oct4 
and CD31 surface markers were observed, which constitute a hallmark of rMAPCs 
undifferentiated stage. Dexamethasone effectively mediated rMAPC osteogenic differentiation by 
inducing the formation of a mineralized collagen type I network, and facilitated the activation of 
the wnt/β-catenin, a crucial pathway in skeletal development. To investigate the genetic 
modification of rMAPCs grown as 3D aggregates prior to implantation, scAAV serotypes 2, 3, 
and 6 were evaluated. scAAV6 packaged with the enhanced green fluorescent protein expression 
cassette efficiently mediated long-term transduction (10 days) “in vitro” and “vivo”. The reporter 
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transduction event allowed the tracing of OD-rMAPC (induced by dexamethasone) aggregates 
following OD-rMAPC transfer into a macro-porous hydroxyapatite scaffold implanted in a rat 
calvaria model. Furthermore, the scAAV6-transduced OD-rMAPC generated a bone-like matrix 
with a collagenous matrix rich in bone specific proteins (osteocalcin and osteopontin) in the 
scaffold macro-pores 10 days post-implantation. Newly formed bone was also observed in the 
interface between native bone and scaffold. The collective work supports future bone tissue 
engineering applications of 3D MAPC cultures for expansion, bone formation, and the ability to 
genetically alter these cells using scAAV vectors.
INTRODUCTION
Stem cell-based clinical applications require both a large quantity of cells and an effective 
expansion technology with a reproducible differentiation protocol for bone formation and 
regeneration of large skeletal defects. Multipotent adult progenitor cells (MAPC) are a bone 
marrow subpopulation of stem cells characterized by high levels of CD31 and Oct4. This 
latter marker is crucial for their extensive self-renewal ability as revealed in embryonic stem 
cells (ESCs).[1] Besides its self-renewal advantage, MAPC also present more 
homogeneity[1] when compared to mesenchymal stem cells (MSC), and the clinical grade 
human MAPCs (Multistem®) offer therapeutic relevance as a immunomodulatory treatment 
tool for certain diseases (ClinicalTrials.gov NCT00677859, NCT00677222).[2] However, 
little is known about the clinical potential of MAPC to form bone tissue, and also on the 
phenotypic and genotypic expression pattern during MAPC osteogenic differentiation. 
Furthermore, combined applications of MAPC and adeno-associated viral (AAV) vectors in 
bone tissue engineering have been deferred until AAV cytotoxicity and transduction 
efficiency are thoroughly investigated.
Recently, the rat MAPC (rMAPC) line has been shown to have a high expansion rate when 
cultured as static three-dimensional (3D) cell aggregates.[3] These cell aggregates retained 
their pluripotency state for at least 16 days.[3] More importantly, researchers have 
demonstrated that 3D static aggregate stem cell cultures are robust bioprocesses for MAPC 
expansion that offer safety advantages over suspension cultures. [3,4] Unlike suspended 
aggregates, static ESC cultures do not form invasive tumors after “in vivo” transplantation.
[4] Moreover, adult stem cells (like MSCs) are known to differentiate in the presence of 
bone signaling cues, such as dexamethasone and bone morphogenetic protein-2 (BMP-2) 
through wnt/β-catenin pathways.[5,6] In our preliminary studies with 2D cultures, 
dexamethasone positively modulated the osteogenic differentiation of rMAPCs, but not 
exogenous recombinant human BMP-2, a potent osteogenic growth factor. Thus, it would be 
important to test the reproducibility of dexamethasone osteogenic effects in 3D aggregate 
systems, since the 3D system better mimics the “in vivo” environment with a higher 
expansion capability.[3,5] Interestingly, 3D cultures of human ESCs have also been 
confirmed as a viable alternative to monolayer 2D systems, and possess a significant “in 
vivo” reproducibility after long-term culture.[7] Therefore, this study focused on 
investigating rMAPC 3D aggregate static long-term cultures for cell expansion and 
osteogenic differentiation induced by dexamethasone.
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In addition to applications of MAPCs for characterization of bone formation in large skeletal 
defect models, the therapeutic potential of transgenic MAPCs is also of particular interest. 
For example, multipotent or differentiated MAPCs could be altered to express or secrete 
endogenous factors involved in local bone formation, such as BMPs as in other bone 
fracture healing models.[11] In addition, MAPCs could be labeled (i.e. with the green 
fluorescent protein) for “in vivo” tracing of cell replication and migration “in vivo”. 
Currently, viral gene delivery vectors have demonstrated success for the efficient 
transduction of a wide variety of cell types “in vivo” and “ex vivo”.[12] In particular, 
recombinant adeno-associated virus (rAAV) offer a broad tropism and have demonstrated 
success in “in vivo” applications.[12, 13] While several studies have demonstrated MSC 
transduction by single-strand rAAV serotypes 2, 3 and 6 “in vitro” [14, 15], to our 
knowledge none have evaluated the transduction of self-complementary rAAV vectors in 
MAPCs for “in vitro” and/or “in vivo” applications in large calvaria bone defects within a 
non load-bearing environment. These critical-size large defects (CSD) do not heal by 
themselves, and therefore, they may need a combination of MAPC-based bone tissue 
engineering approaches and AAV vector technologies for bone formation to occur.
Thus, our hypotheses test whether a 3D cell culture system can provide a large number of 
rMAPCs for (1) osteogenic differentiation with dexamethasone supplementation and (2) 
rAAV-mediated gene transfer for “in vivo” bone formation in calvaria large defects. The 
transduction efficiency of rAAV serotypes on multipotent and differentiated rMAPCs was 
investigated and a transgenic reporter used to track rMAPC aggregates “in vivo” in 3D 
scaffolds in rat calvaria CSD. This “in vitro” 3D culture system may allow the expansion, 
bone formation, and effective AAV-based gene delivery for “in vivo” bone healing 
therapies.
RESULTS
1. Expansion and viability of the 3D rMAPC aggregates
Rat MAPC (rMAPC) in 3D aggregates grew steadily up to day 4, increasing from 
approximately 1,500 up to a mean of 10,548 viable cells per aggregate (Figure 1a). After 
day 4, the number of viable cells decreased substantially, which is possibly related to the 
low volume of the growth medium (Figure 1a) (p<0.001). Also, the doubling time was 
consistently 37h through all 4 days of the 3D aggregate culture, and then decreased 
substantially thereafter. The population of viable cells outstand the dead/damaged cells seen 
by the large viable-associated red fluorescence 2D plane of the aggregate (Figure 1b). Also, 
rendering a 3D volume view of the aggregate revealed a large population of viable cells 
clustered together to form a rounded aggregate as seen in the 2D view (Figure 1b, c).
Similar to the cell aggregate growth curve, there was also an increase in cell aggregate 
diameter. After the centrifugal settling to the bottom of a well, single cells clustered together 
to an average diameter of 333μm. Aggregates then increased in size to about 397 μm 
diameter by 96 h (4 days) after the initial agglomeration (p<0.001), and after that point the 
size of the aggregate remained unchanged (Figure 1d).
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After 4 days of rMAPC aggregate expansion, flow cytometry revealed that the cells in the 
aggregate retain their positive levels for the rMAPC pluripotent marker Oct4 and the 
rMAPC marker CD31 (Figure S1). This latter marker is highly expressed in undifferentiated 
MAPC, and therefore is used as an hallmark with Oct4 to confirm rMAPC’s undifferentiated 
state.[1] This was also confirmed at the transcript level, where expression of Oct4 and CD31 
remained high at day 4, when compared to baseline levels before expansion started (Figure 
S1).
2. AAV cytotoxicity and transduction efficiency on rMAPC aggregates
To investigate gene delivery to rMAPCs in the 3D aggregate culture, a self-complementary 
(sc) CMV-eGFP expression cassette was packaged in capsids previously reported to be 
capable of MSC transduction.[14] After scAAV-GFP vector transduction at a multiplicity of 
infection (MOI; viral genomes/cell) of 100, no differences in cell viability were observed 
between undifferentiated and differentiated rMAPC aggregates for serotypes AAV3 and 
AAV6(Figure 2a). For AAV2, viability of differentiated rMAPC aggregates was similar to 
untransduced cells (Figure 2a). However, there was a significant decrease in cell viability 
when comparing AAV2-treated undifferentiated and differentiated rMAPC cultures (p≤0.01) 
(Figure 2a).
In general the transduction efficiency of different scAAV serotypes, as measured by a GFP+ 
phenotype, was greater in differentiated aggregate cultures compared to undifferentiated 
cells (Figure 2b). Among the tested serotypes, AAV6 serotype presented the highest 
percentage of GFP+ cells after 3 days when compared to AAV2 (p=0.0073) and to AAV3 
(p=0.0068). Expression of GFP increased up to day 7 in AAV6-transduced cultures (Figure 
3a), and afterwards, cells continued to express GFP through day 14 (Figure 3 b-e).
3. Bone-like matrix derived from dexamethasone-treated rMAPC aggregates
Since effective gene delivery was demonstrated in 3D cultures, we next sought to investigate 
the effects of dexamethasone on the bone matrix generation and mineralization. Cell/matrix 
cryo-sections were analyzed after differentiation of rMAPC aggregates was induced by 
osteogenic media with and without dexamethasone (OMD and OM, respectively) and by 
basal media (BM) without dexamethasone and osteogenic supplements. Unlike in OM and 
BM treatment, dexamethasone-treated aggregate cultures were highly immunoreactive to 
collagen type I antibody and a collagenous fiber network could be observed (Figure 4a). The 
orange/redness of collagen fibrils could also be appreciated under polarized light after picro-
sirius red staining, consistent with a high level of maturation of the collagen (Figure S2c).
[16]
Electron microscopy images of the rMAPC aggregate matrices at day 38 confirmed the 
abundant matrix mineralization in dexamethasone cultures (Figure 4b) indicated by large 
areas of long spindle-like crystals (white arrows). On demineralized sections at an earlier 
time point (day 27), few matrix demineralized areas were observed, as well as a densely 
compacted matrix which possessed regions with typical collagen D-periodicity (data not 
shown). On the other hand, matrix-formed crystals were scarce and short in length in 
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cultures grown in the absence of dexamethasone (Figure 4d). In rMAPC aggregate matrices 
grown in basal medium no crystals were observed (Figure 4f).
All these matrix features in OMD cultures resembled natural bone tissue. On the contrary, 
aggregate cultures without dexamethasone (both OM and BM cultures) showed poorly 
mineralized matrices with scarce collagen type I (Figure 4c, e). In addition, all matrices in 
dexamethasone medium stained poorly for lipid deposits (red deposits stained by Oil red O 
in Figure S2a) and for proteoglycans (orange/red areas stained by Safranin O in Figure S2b).
[6] These observations indicate that dexamethasone-treated rMAPC aggregates committed 
to an osteogenic phenotype and not to adipogenic or chondrogenic lineages.
4. Dexamethasone increases expression of mesoderm and bone markers in rMAPC 
aggregates
After undergoing a dexamethasone-enriched osteogenic differentiation protocol for 38 days 
in 3D cultures, Oct4 mRNA levels in rMAPC decreased significantly to an average ΔCT of 
approximately 2 compared to baseline levels (Fold change=0.7, Figure 4g) (p=0.019). This 
observation was consistent with other literature[3] and was seen at a lesser extent in cultures 
treated without dexamethasone (OM: average ΔCT=3, Fold change=0.9), suggesting that 
dexamethasone is inducing rMAPC differentiation. The alpha-fetoprotein (Afp) transcript, 
which is usually upregulated on differentiated cells, was expressed at high levels in 
osteogenic culture medium without dexamethasone (OM) but without significance and to a 
lesser degree in dexamethasone-enriched media (OMD) with significance (p<0.01) (Figure 
S3). At the terminus of the differentiation process, the endothelial-specific marker CD31 
was significantly downregulated in both media without dexamethasone (p=0.003928) and 
with dexamethasone (p=0.035557), ruling out a possible endothelial commitment (Figure 
4h). Also, Kdr, a mediator of VEGF-induced endothelial proliferation and differentiation, 
was found downregulated in dexamethasone-supplemented cultures (Figure 4h). More 
importantly, mesoderm-specific transcripts such as BMP-2 (p=0.039) and BMP-4 (p=0.015) 
were found highly upregulated by dexamethasone, and to lesser extent in OM without 
dexamethasone (Figure 4h). Essential mid- to late-stage osteogenesis markers signaling 
molecules were assessed, particularly Col1a2, osteopontin (OSP), and osteocalcin (OCN) 
(Figure 4i). The late bone-specific gene, OCN (Figure 4i), was found highly upregulated 
with dexamethasone when compared to medium without dexamethasone (p=0.014). 
Collagen type 1 (Col1a2) and osteopontin (OSP) early bone markers were overexpressed 
relative to baseline (Figure 4i); however, transcript expression was without significance for 
Col1a2, perhaps due to the ongoing late stage of bone development (38 days) on 
dexamethasone culture conditions (OMD). In summary, overexpression of mesodermal and 
late bone-specific genes in OMD confirmed their osteogenic potential under dexamethasone 
supplementation in this 3D culture system.
5. Nuclear co-localization of β-catenin increased in rMAPC aggregates treated with 
dexamethasone
After confirming the osteogenic potential of rMAPC aggregates, we assessed the activation 
of the wnt/β-catenin pathway, crucial on skeletal development. Expression of nuclear β-
catenin was evaluated during the osteogenic differentiation in medium with and without 
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dexamethasone. To confirm the translocation of the β-catenin to the nucleus and inhibition 
of β-catenin degradation, the expression of the activated form of GSK3 (p-GSK3 Tyr 
216/279) that sequesters and negatively regulates β-catenin activation was also assessed. The 
β-catenin is only activated when a Wnt signal is present and p-GSK3 kinase activity is 
inhibited.[6] Upon activation β-catenin is mainly found free and co-localized with the 
nucleus, and this was demonstrated only in dexamethasone-differentiated rMAPC cells 
(Figure 5a). Conversely, in OM without dexamethasone (OM), β-catenin was found outside 
the nucleus and closely associated with the plasma membrane, which suggests that this 
molecule is inactive, and therefore, no wnt signaling occured (Figure 5b). These 
observations were supported by the lack of expression of the β-catenin negative regulator p-
GSK3 in dexamethasone-treated cultures (Figure 5c) and by its abundant expression in 
culture media without dexamethasone (OM) (Figure 5d).
6. AAV6 transduction for “in vivo” rMAPC tracing and bone formation
After efficient osteogenic differentiation conditions were set for the aggregates, we then 
used the AAV6 serotype to both trace the differentiated aggregates “in vivo” and study its 
effects on bone formation. The ability of scAAV6 to label differentiated rMAPC for “in 
vivo” tracing was investigated on a macro-porous hydroxyapatite-based 3D scaffold. In 
these experiments, osteogenically differentiated rMAPC or OD-rMAPC aggregates 
(dexamethasone-treated at day 38 of differentiation) were transduced with scAAV6-CMV-
eGFP at a MOI of 100. On the following day, these transduced aggregates were loaded into 
macro-porous hydroxyapatite-based scaffolds, which were then implanted in a rat calvaria 
CSD bone formation model. Four and ten days after “in vivo” implantation of porous 
scaffolds with AAV6-transduced rMAPC, tracing of transduced cells revealed GFP+ cells 
on the porous areas around the scaffold materials (Figure 6 a-e). The number of GFP+ cells 
appeared to be higher at 10 days than at 4 days of post-implantation (Figure 6f).
Importantly, untransduced and AAV6-transduced rMAPCs generated a osteogenic-like 
tissue expressing late specific bone markers (such as osteopontin and osteocalcin) within the 
macro-pores of the 3D scaffold after 10 days (Figure 7 a-b, d-e). Furthermore, transplanted 
AAV6-transduced rMAPCs formed a bone-like collagenous matrix with osteocyte-like cells 
entrapped in lacunae within the macro-pores (Figure 7g-h). Also, newly formed bone was 
visualized at the native bone-scaffold interface 10 days after implantation of transduced cells 
(Figure 7i). These observations indicate that rAAV6 transduction allows for “in vivo” bone 
formation and mediates stable gene transfer to differentiated rMAPC aggregates, which 
remains strong post-implantation while not affecting the osteogenic differentiation of 
rMAPCs. Lastly, Oct4 expression was not detected in GFP+ cells “in vivo” after 10 days, 
and therefore, the presence of cell growth from day 4 to 10 was not related to the presence of 
immortalized rMAPC (Figure 8).
DISCUSSION
Stem cell-based approaches are valuable tools not only for the formation of new tissues like 
bone, but also when used as models of bone disease and to understand bone development.
[17, 18, 19] Rat and human MAPCs have been used as cell-based therapies for newly 
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formed tissues in rodent studies [20, 21], and MAPC-based clinical trials have been initiated 
to take advantage of MAPCs immunomodulatory effects (ClinicalTrials.gov NCT00677859, 
NCT00677222). Our current study successfully combined for the first time osteogenically 
differentiated rat MAPC (OD-rMAPC) and AAV vector mediated gene delivery for the final 
purpose of bone formation in a calvaria critical-size defect (CSD) model.
Rat calvaria “in vivo” CSD models require a large number of cells, which often rely on 
growth in cell scale-up bioprocesses.[5, 22, 23] Despite several innovations in these robust 
bioprocesses, progress has been slow due to cellular heterogeneity including karyotypic 
abnormalities associated with prolonged “ex vivo” culture times, which make stem cells 
unfit for clinical use.[24, 25, 26] However, in this studywe used a cell line (rMAPCs) with 
high self-renewal ability and homogeneity, and thus we were able to expand rMAPCs on 
static 3D aggregate culture systems for a short time period (4 days). Recently, rMAPC have 
shown to possess a high expansion rate with a doubling time of about 23h in 3D suspension 
cultures.[3] In our study, the doubling time was consistently 37h through all 4 days of the 
3D aggregate culture. The lower doubling time reported by Subramanian et al.[3] is 
probably related with the different cell counting protocol used. Determining the viable cell 
population was a more appropriate approach in this study, since poor diffusion of oxygen 
and essential nutrients to the center of the aggregate has been found to compromise cell 
survival and increase Oct4 mRNA levels.[4] Though, the expansion observed here as cell 
aggregates did not compromise the viability of the cells (approximately 85-95% of viability/
aggregate), particularly in the center of the aggregate as seen by the large viable-associated 
red fluorescence (Figure 1b). In the periphery of the aggregate few nonviable cells were 
observed, but those were attached to the bottom of the well and not clustered to the 
aggregate. The 3D volume view of the aggregate revealed a large number of viable cells 
clustered together to form a robust rounded aggregate of about 400 μm in diameter. At the 
end of expansion, cells in aggregates retained their initial rMAPC undifferentiated state, as 
seen in other studies.[3]
After an appropriate expansion method was found, we tested the osteogenic potential of 
rMAPC aggregates under different media conditions with and without dexamethasone. 
Dexamethasone appears to drive commitment of rMAPC aggregates to an osteogenic 
phenotype and not to chondrogenic, adipogenic or endothelial lineages, since: i) matrices 
had little proteoglycans and lipids deposits (Figure S2), and ii) differentiated cells had the 
endothelial cell marker CD31 downregulated at the mRNA and protein levels (Figure 4h). 
At the transcriptional level, dexamethasone also significantly increased the expression of 
late bone-specific markers (osteocalcin) and endogenous osteogenic growth factors (BMP-2 
and BMP-4) (Figure 4h). Formation of collagen type I and of large areas of long spindle-like 
crystals and crystal nucleation was seen on matrices when dexamethasone was 
supplemented, which indicates that normal calcification occurred (Figure 4a-b). Dystrophic 
(or abnormal) calcification has been reported elsewhere when organic phosphates are added 
to osteogenic culture medium.[27, 28] On the other hand, our cultures without 
dexamethasone had the crystal nucleation and formation drastically impaired (Figure 4c-f).
In preliminary monolayer culture studies, dexamethasone stimulated rMAPC to form a 
bone-like matrix in vitro and increased ALP activity at early stages. In this study, 
Ferreira et al. Page 7













dexamethasone-enriched medium induced the translocation of the β-catenin molecule to the 
nucleus during rMAPC differentiation (Figure 5a), suggesting the activation of the wnt/β-
catenin pathway. Elucidating the role of dexamethasone in the activation of the β-catenin 
pathway is important, since this pathway was found to be essential in skeletal development, 
and stem cell fate.[9, 10, 29, 30] Here in 3D aggregate cultures, we found that 
dexamethasone also increased the nuclear β-catenin at the terminus of rMAPC osteogenic 
differentiation, like in MSCs.[31] The free translocation of β-catenin to the nucleus was 
confirmed by the absence of GSK3 (Figure 5c). Besides the presence of wnt, the β-catenin 
signaling requires the inhibition of GSK3 kinase activity, since the active form of GSK3 
targets β-catenin for proteasomal degradation.[30] The GSK3-β-catenin degradation 
complex is activated when a specific tyrosine is phosphorylated at GSK3.[32, 33] 
Conversely, in medium without dexamethasone (OM), the β-catenin was not found in the 
nucleus in the presence of an abundant p-GSK3 kinase, which targets β-catenin for 
degradation and restricts its nuclear translocation. The concomitant activation of the β-
catenin pathway and inhibition of the GSK3 kinase activity has been reported and 
extensively reviewed in literature.[30, 34, 35, 37] The interaction of the BMP and wnt 
pathways seems to be particularly complex in bone development.[31, 37, 38] The existence 
of different levels of crosstalk between BMP and wnt has been recently confirmed during 
the differentiation of the Drosophila mesoderm and of other stem cell lineages.[31, 37, 39] 
Nevertheless, these complex interactions are far away from being fully understood and 
further research is mandatory for later bone regeneration applications.
AAV vectors are proving to be increasingly effective because of their superior safety profile 
and “in vivo” sustained transgene expression[40, 41], including their ability to transduce 
nondividing primary cells[42] and certain adult stem cell lineages.[14, 15, 43] The results 
present herein suggest that safe, efficient, and long-term OD-rMAPC aggregate transduction 
is feasible through 14 days “in vitro” and 10 days “in vivo” for rat calvaria defects 
(endpoints of the study) through the use of scAAV6 vectors (Figures 3 and 6). Importantly, 
gene transfer with self-complementary AAV6 (scAAV6) didn’t affect the osteogenic 
differentiation of rMAPC or the proliferation of these osteoblast-like cells (Figure 7). 
Undifferentiated aggregates displayed reduced transduction efficiency with the three 
analyzed scAAV serotypes, and an increase cytotoxic trend, particularly with scAAV2 
(Figure. 2). To our knowledge, this is the first report comparing the scAAV transduction 
efficiency in undifferentiated versus differentiated MAPC using a 3D culture system. As 
previously mentioned, the therapeutical potential of human MAPC cells is currently being 
tested in clinical trials.[2] This fact plus the stable transduction efficiency seen here with 
scAAV6, makes the MAPC 3D aggregate system an ideal cell-based therapy for AAV6-
mediated gene delivery. Compared to previous literature[14], levels of AAV6 transduction 
efficiency on rMAPC were significantly higher (15-27% up to day 7) at lower MOIs (100) 
than with human MSCs at MOIs of 107 (<0.5%). Yet, further studies are needed focusing on 
AAV transduction efficiency of human MAPCs because efficient gene transfer decreases 
significantly from nonhuman primates to humans when using marrow-derived adult stem 
cells (MSCs).[14] More interestingly, our 3D hydroxyapatite macro-porous scaffolds loaded 
with untransduced and transduced OD-rMAPC aggregates generated a bone-like tissue 10 
days after implantation in calvaria CSD models that do not heal by themselves (Figure 7). 
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These findings indicate this scAAV6 technology could be used with rMAPC for future bone 
regeneration approaches with porous 3D hydroxyapatite-based scaffolds. Nevertheless, 
optimal conditions for the complete regeneration of this calvaria defect model by MAPCs 
have yet to be established, as well as for load-bearing defect models (e.g. femur).
In conclusion, the results demonstrate that rMAPC in this 3D culture system can be a 
feasible model to effectively generate valuable sources of: (1) rMAPCs, and (2) OD-
rMAPCs intended for transplantation with macro-porous 3D scaffolds for “in vivo” bone 
formation in calvaria. When transplanted to scaffolds, the scAAV6-transduced and 
untransduced OD-rMAPC can form a bone-like tissue at initial bone healing stages. Future 
advantages of this model include 1) to engineer bone tissues using a MAPC-based scaffold 
construct after longer implantation periods, and 2) to study bone development, including the 
crosstalk levels between BMP and wnt pathways.
MATERIALS and METHODS
1. MAPC isolation and maintenance
Multipotent adult progenitor cells (MAPCs) derived from rat bone marrow (rMAPC) were 
isolated and characterized at the University of Minnesota Stem Cell Institute according to a 
well-established protocol.[44,45] Briefly, six to ten million cells were plated in MAPC 
growth medium. The plates were incubated in a humidified incubator at 37°C with 5% O2 
and 5–6% CO2. After 4 weeks of culture, cells were depleted of CD45 and Ter119 using 
magnetic microbeads and the remaining cells were seeded. After 3–14 weeks, cells with a 
typical spindle-shaped rMAPC morphology appeared. To confirm that these clones were in 
fact MAPC, the level of Oct4 mRNA was determined using quantitative RT-PCR and the 
presence of CD31, typical for rMAPC was analyzed by fluorescence-activated cell sorting 
(FACS). Once a cell line with rMAPC phenotype (Oct4 mRNA at ΔCt of 4–6, and CD31 
positive) was derived, a large frozen working cell bank was prepared. The characteristics of 
the putative rMAPC were then evaluated (endothelial, hepatocyte, and neural precursor-like 
differentiation; and further transcriptome phenotype) as previously described.[1] During 
subsequent cell expansion/maintenance, quality control studies were performed up to 
passage 30. Rat MAPC cells from passage 20 were used for all the experiments of the 
present study.
2. rMAPC Growth and Osteogenic Medium
Briefly, rMAPC growth medium consisted of a 60/40 (v/v) mixture of low glucose DMEM 
(Gibco, CA) and MCDB-201 (Sigma, MO) supplemented with 0.026 μg/mL ascorbic acid 3-
phosphate (Sigma), linoleic acid bovine serum albumin (LA-BSA, Sigma) (103 μg/mL BSA 
and 8.13 μg/mL linoleic acid), insulin-transferrin-selenium (ITS, Sigma) (final concentration 
10 μg/mL insulin, 5.5 μg/mL transferrin, 0.005μg/mL sodium selenite), 0.02 μg/mL 
dexamethasone (Sigma), 4.3 μg/mL β-mercaptoethanol and 2% (v/v) qualified fetal bovine 
serum (FBS, Hyclone, IL). Three growth factors were also added to the media: human 
platelet derived growth factor (PDGF-BB, R&D Systems, MN) (10 ng/mL), mouse 
epidermal growth factor (EGF, Sigma) (10 ng/mL), and mouse leukemia inhibitory factor 
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(LIF) (103 Units/mL) (Chemicon, ESGRO). All media were also supplemented with 100 
IU/mL penicillin and 100 μg/mL streptomycin (Lonza, MD).
Basal medium (BM) composition consisted of 60/40 (v/v) mixture of low glucose DMEM 
and MCDB-201 supplemented with LA-BSA (103 μg/mL BSA and 8.13 μg/mL linoleic 
acid), ITS (final concentration 10 μg/mL insulin, 5.5 μg/mL transferrin, 0.005μg/mL sodium 
selenite), 4.3 μg/mL β-mercaptoethanol and 10% FBS. Basal media did not have 
dexamethasone supplementation. Osteogenic medium (OM) was composed of BM with the 
addition of 10mM of β-glycerophosphate (Sigma) and ascorbic acid at 0.2mM (Sigma) with 
or without dexamethasone supplementation at 10−7M (OMD and OM, respectively).[45]
3. Cell culture systems
Rat MAPCs (rMAPC) were cultured either as three-dimensional (3D) aggregates or as 
monolayer (2D) cell culture systems in an incubator at 37°C, 5% CO2 and O2 while in 
growth media, and when differentiation media (OMD, OM, BM) was supplemented, cell 
cultures were changed to normal O2 levels.
For the 3D aggregate system, 1-2×103 MAPC cells were seeded in suspension with MAPC 
growth medium in 96-well rounded bottom ultra-low attachment plates (Costar), using a 
modification of a forced aggregation method previously reported.[3, 46] Cells in suspension 
were centrifuged at 1400 rpm for 4 minutes to allow cells to settle to the bottom of the well 
and form aggregates over time. Aggregates were allowed to grow for 5 days, and cell 
viability and diameter of aggregates was monitored at day 1, 2, 3, 4 and 5 (see protocol 
below). Then, at day 4 ten 3D aggregates were transferred to each well on 24-well ultra-low 
attachment plates (Costar), and the medium was completely changed to either BM, OM and 
OM with dexamethasone (OMD). OM and BM had no dexamethasone supplementation. 
Medium change took place every 2-3 days. All of these 3 culture conditions (BM, OM and 
OMD) were evaluated for osteogenic differentiation. Differentiation was terminated at both 
27 and 38 days.
For the 2D monolayer cultures, 8×104 rMAPCs were seed with rMAPC growth medium in 
24-well flat plates with regular attachment properties (Costar). Cells were allowed to grow 
for 4-5 days until they reach the 80-90% of confluency for mesodermal differentiation. 
Then, growth medium was completely replaced by either OMD, OM or BM conditions, to 
study the osteogenic potential of the rMAPC aggregates using these three culture conditions. 
Media change took place every 2-3 days. All these culture conditions (OM and OMD) were 
evaluated for osteogenic differentiation. Differentiation was terminated at both 21 and 42 
days.
4. Cell Viability and rMAPC 3D Aggregate Diameter
During the 4 days of rMAPC aggregate growth, cell viability and proliferation in the 
aggregates was assessed by a CellTiter 96 Aqueous One Solution assay kit (Promega, WI) 
according to the manufacturer. Briefly, this kit contains a MTS compound that is bioreduced 
by cells into a colored formazan product. The quantity of formazan product was measured 
by the amount of 490nm of absorbance which is directly proportional to the number of 
living cells in culture. In order to perform the assay, 20ul of CellTiter 96 solution was added 
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to the media with gentle shaking. Plates were then placed in incubator for about 2h at 37°C, 
5% CO2 and 5% O2. Background absorbance from negative controls (without cells) was 
typically 0.206-0.216 for all wells; this average background was subtracted from all 
absorbance values of experimental groups for normalization. Eight biological replicates 
were run at day 0, 2, 4 and 5. The cell number was determined by performing cell titration.
A Live/Dead® Cell Vitality Assay C12-resazurin/SYTOX® Green kit (L34951, Molecular 
Probes, Eugene, OR) was used to visualize the cell viability status within the 3D aggregate 
according to the manufacturer. Briefly, the aggregates were incubated at 37°C for 15 
minutes with the kit working solutions. Metabolically active cells will stain red fluorescent 
color, and stain damaged or dead cells in green. Fluorescence was observed by microscopy 
with bright field, TRITC and FITC filters with Nikon Eclipse Ti-U camera (Nikon, Japan), 
and Nikon NIS Elements software was used to render the 2D and 3D images of the 
aggregate. The diameter of five cell aggregates was recorded from day 0 to 5 with light 
microscopy using previous Nikon camera and software.
5. Intracellular Staining for Oct4 and CD31 by Flow Cytometry
The protocol used for MAPC characterization by flow cytometry has been published 
elsewhere.[1, 45] Briefly, after 4 days of MAPC aggregate expansion (in growth media), 
cells were harvested by trypsinization of aggregates were washed with and suspended in 
PBS with 3% (v/v) serum at 100,000 cells per tube. After fixing and blocking for 1h, cells 
were incubated with antibodies against Oct4, CD31 and CD44 to confirm whether cells 
retained the levels of these undifferentiated rMAPC markers.
6. Histological analysis of 3D aggregate matrices
On day 27 and 38, cell/matrix layers from 3D aggregate and 2D cultures, were washed with 
calcium-free PBS 1x and fixed. Cryosections with approximately 5μm thickness were made 
from the rMAPC aggregate matrices. For collagen maturation, matrix cryosection slides 
were stained for 1h in 0.1% solution of Sirius red dissolved in aqueous saturated picric acid 
(Electron Microscopy Sciences, PA) for collagen identification.[16] Slides were dehydrated 
in gradient ethanol, followed by xylene treatment and resin mounted. Stained cell/matrix 
layers were visualized and photographed with a Nikon Eclipse Ti-U with an Olympus DP70 
camera (Japan) on polarized light.
For cartilage tissue analysis, cryosections were stained using a Safranin O staining protocol. 
Briefly, cryosection slides were stained with Weigert’s iron hematoxylin working solution 
for 10 minutes, washed in water , stained with Fast Green solution for 5 minutes, rinsed 
quickly with 1% acetic acid solution for 10 –15 seconds, and stained in 0.1% safranin O 
solution for 5 minutes. Dehydration followed and mounting followed.
Lipid deposition in cell matrices was evaluated using Oil Red O staining protocol after 
fixation of cryosection slides. Briefly, cell/matrices layers were rinsed with 60% 
isopropanol, stained with freshly prepared Oil Red O working solution 15 min (Electron 
Microscopy Sciences, PA), rinse with 60% isopropanol and stained with Harris Hematoxylin 
for nuclei counterstain. All cell/matrices layers were visualized under light microscopy 
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(Nikon Eclipse Ti-U, Japan with an Olympus DP70 camera). Matrices stained with Picro-
sirius Red solution were observed under polarized light to view collagen organization and 
maturation. All experiments were run in triplicate.
7. Immunohistochemistry
Rat MAPC aggregates/matrix cryosections were fixed with 4% paraformaldehyde (PFA), 
rinsed, endogenous peroxidase activity was inhibited by incubating for 30 min with 0.3% 
H2O2 in 100% methanol, rehydrated, and transferred to PBS–Triton solution.
For collagen type I, avidin/biotin activity was blocked in the cryosections with Avidin-
Biotin kit (Dako, CA), rinsed thrice with PBS plus Triton X and unspecific antibody binding 
sites were blocked for 30 min with 0.4% fish skin gelatin in PBS. Then, cryosections were 
incubated overnight at 4°C with rabbit primary antibody against rat collagen type I 
(NB600-408, Novus Biologicals, CO), rinsed thrice, and incubated with secondary 
biotinylated goat anti-rabbit IgG antibody (NB730-B, Novus Biologicals) for 30 min at RT. 
The cell/matrix layer was incubated in ABC complex (Vector Laboratories, CA) according 
to the manufacturer’s protocol, rinsed thrice, and DAB Chromogen solution (Dako, CA) was 
added to the matrix layer for 5-20 minutes until brown color developed. Positive controls 
with collagen type I matrices produced by osteoprogenitor cultures (MC3T3-E1) and 
negative controls containing a gelatin substrate were also stained. Cell/matrices layers were 
visualized under light microscopy.
For β-catenin and active form of GSK3α/β immunostaining, cryosections were incubated 
overnight at 4°C with either goat primary antibody against rat β-catenin (C-18) (sc-1496, 
Santa Cruz Biotechnology, CA) or p-GSK3α/β (Tyr279/Tyr216) (sc-11758, Santa Cruz), 
rinsed thrice, and incubated with secondary donkey anti-goat DyLight649-conjugated IgG 
antibody (705-496-147, Jackson ImmunoResearch, PA) for 30 min at RT. Then, 
cryosections were counterstained with DAPI nuclei kit (Millipore, Billerica, MA) for 5 min. 
Sections with primary rat osteoblast cultures were used as positive controls to view β-
catenin translocation from the plasma membrane to the nucleus. β-catenin, GSK3α/β and 
nuclei were observed under fluorescent microscopy (Nikon Eclipse Ti-U with Nikon Digital 
sight DS-Qi1Mc camera, Japan) with TRITC and DAPI filters, respectively; photos were 
taken for each filter and then merged together.
8. Transmission Electron Microscopy
On day 27 and 38 of differentiation, 3D aggregate cells/matrices were washed twice with 
PBS 1X and fixed in 2.5% glutaraldehyde, 2% paraformaldehyde in 0.1M sodium 
cacodylate buffer (pH 7.4). For decalcification, a 0.1M EDTA solution was used for 2 days 
buffered with 0.15M sodium phosphate, at pH 7.4, 4°C. Then samples were post-fixed in 
potassium ferrocyanide reduced osmium (1% osmium tetroxide/1.25% potassium 
ferrocyanide/0.15M sodium phosphate, pH 7.4) for 1 h. For undecalcified samples, after the 
ethanol dehydration series, propylene oxide was used as an intermediate solvent, followed 
by incubation in a solution of propylene oxide and Polybed 812 resin for 2 h, samples stayed 
overnight in Polybed 812 resin, and then polymerization was achieved in the tube for 24 
hours at 60°C. Ultrathin sections with 70nm thickness were cut, stained with uranyl acetate 
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and lead citrate, and observed using a LEO EM-910 transmission electron microscope 
operating at 80kV (Carl Zeiss SMT, Peabody, MA), and images were taken at 
2,000-50,000X using a Gatan Orius SC1000 CCD camera with Digital Micrograph 3.11.0 
(Gatan, Inc., Pleasanton, CA) at the Microscopic Services Laboratory (MSL) at the 
University of North Carolina. Matrices/cell layer sections from differentiated osteoblast-like 
murine-derived clonal MC3T3-E1 cell lines were used as a positive control for comparison 
purposes with OD-rMAPC.
9. Gene Expression Arrays
Rat MAPCs were collected from aggregate cultures at baseline (day 0), day 4 of growth, and 
day 38 of differentiation in three media conditions (BM, OM and OMD) with TRIzol 
reagent (Invitrogen) for total RNA extraction, according to manufacturer protocol. Total 
RNA purification was performed with a RNeasy Mini Kit (Qiagen). Reverse transcription to 
cDNA was achieved by mixing 500ng of total RNA with a first strand cDNA synthesis mix 
(from RT2 First Strand Kit C-03, SABiosciences, MD), based on established manufacturer 
protocol. Real-time PCR reaction was accomplished by adding RT2 qPCR Master Mix (RT2 
SYBR Green/ROX qPCR Master Mix, SABiosciences, MD) to the first strand cDNA 
synthesis reaction at room temperature; the cocktail mix was dispensed into a 96-well plate 
rat osteogenesis customized RT2 Profiler PCR array (array CAPR09685, SABiosciences, 
MD), which was then run in a 7500 Real Time PCR System. Three biological replicates 
were analyzed for each experimental group, and the fold change was calculated relative to 
day 0 (baseline) and normalized to the mean expression of three house-keeping genes 
(Rpl13a, Ldha, Actb). If fold change >1, this indicates an up-regulation of the gene; if fold 
change <1, it will indicate a down-regulation. The SABiosciences web-based platform was 
used for PCR data analysis. The mRNA expression of the following genes was analyzed: 
Smad1, Runx2, Sox9, Osx (osterix), Col1a2 (collagen type I alpha 2 chain), OSP 
(osteopontin), OCN (osteocalcin), BMP-2, Oct4, BMP-4, Kdr, Afp, and CD31.
10. In vitro AAV transduction
Recombinant self-complementary AAV-CMV-eGFP vectors serotypes 2, 3B and 6 were 
produced using our previously described triple transfection protocol in human embryonic 
kidney cells.[12, 47] Following transfection, the nuclear lysate was fractionated based on 
density using cesium chloride centrifugation.[47] Fraction samples were then digested with 
DNAseI, subsequently followed by proteinase K digestion, and the remaining viral genomes 
were denatured in a sodium hydroxide solution as described.[47] Alkaline gel 
electrophoresis and southern blotting were used to identify fractions with self-
complementary genomes, which were then pooled and dialyzed in PBS.[48] The viral titer 
was then determined by quantitative PCR using the following GFP primer set: forward 
primer, 5-AGCAGCACGACTTCTTCAAGTCC-3′, and the reverse primer 5-
TGTAGTTGTACTCCAGCTTGTGCC-3. The final titer was then verified by southern 
blotting. Cultures with 3D undifferentiated aggregates (after 4 days of aggregate expansion 
in GM) and 3D dexamethasone-differentiated 3D aggregates (after 15 days in OM plus 
dexamethasone) in 24 ultra-low attachment wells were incubated for 3, 7 and 14 days with 
serotypes AAV2-GFP, AAV3B-GFP and AAV6-GFP at multiplicities of infection (MOI; 
viral genomes/cell) of 100. After trypsinization, cell viability was assessed after 72h of 
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transduction using the CellTiter 96 Aqueous One Solution assay kit as recommended 
(Promega). Also, quantification of rAAV transduction efficiency was performed by 
evaluating GFP positive cells using flow cytometry with dead cell exclusion by gate region. 
Transduction efficiency was monitored for 14 days using fluorescence microscopy and 
photos were taken with FITC filter using the previously mentioned Nikon apparatus.
11. “In vivo” tracing and bone formation with AAV6-GFP-transduced OD-rMAPC 
aggregates
Three-dimensional macro-porous hydroxyapatite-based scaffolds (diameter 8mm and 
thickness 2 mm) developed previously in our lab[48] were used to carry dexamethasone-
treated osteogenically differentiated rMAPC (OD-rMAPC) aggregates after rAAV6 
transduction at MOI 100 into an “in vivo” bone large defect model in calvaria. The defect 
consisted in a 8-mm-diameter calvaria critical-size defect, which has been described.[49] 
Eleven- to thirteen-week-old Sprague-Dawley rats (Charles River, Wilmington, MA) served 
as recipients of the rMAPC aggregate-loaded scaffolds. Rats were anesthetized and an 8-
mm-diameter defect was created on the calvaria bone using a dental drill. Rats were divided 
into scaffold groups with untransduced cell aggregates; and groups with AAV6-GFP 
transduced aggregates.
Four and ten days after surgery, rats were euthanized and the specimens were retrieved for 
decalcification and immunohistological examinations with antibodies against rat GFP, Oct4, 
osteopontin, osteocalcin and rabbit IgG (negative isotype CTL). DAB chromogen solution 
(Dako, CA) was added until brown color developed. Counterstaining with nuclear 
hematoxylin or alcian blue was also performed. Number of GFP+ cells was counted in 5 
random fields in each defect using a microscopy grid of 400×400um. Total of cells was 
calculated towards a total defect area of 33.6mm2. Decalcified specimens were also 
evaluated microscopically for the formation of bone-like matrix and collagen at the 
hydroxyapatite-based scaffold macro-pores and at the native bone-scaffold interface using 
hematoxylin-eosin and Masson’s Trichrome histological staining. The experimental protocol 
for all animal care and use in this study was reviewed and approved by the Institutional 
Animal Care and Use Committee of the University of North Carolina at Chapel Hill.
12. Statistics
Student t-tests were performed in all assays, except for gene expression data, where one-way 
ANOVA analysis was used for multiple statistical comparisons using JMP9 software (SAS 
Institute, NC). Statistical significance was defined at p<0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Rat MAPC expansion and viability during 3D aggregate culture. (a) Cell proliferation in the 
aggregate during 5 days in growth media. Data are shown as mean ±SD of eight independent 
experiments. (b) Cell viability under fluorescence microscopy in one 3D aggregate using a 
non-fluorescent compound that changes to a red fluorescent color when cells are viable and 
metabolically active and changes to green when cells are damaged or dead. The image 
shown is a merge of three images taken with bright field, TRITC and FITC filters. (c) Three-
dimensional rendered image showing viable cells (red) in a 3D aggregate under fluorescence 
microscopy. (d) Aggregate growth in diameter during 5 days in growth media. Data are 
shown as mean ±SD of five independent experiments. *p<0.01 when statistically compared 
to baseline (day 0 or 1).
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Cell viability and transduction efficiency with AAV-GFP serotypes 2, 3, and 6 using 
rMAPC 3D culture system. Percentage of viable undifferentiated and osteogenically 
differentiated rMAPC (OD-MAPC) 72h after transduction with AAV-GFP serotype 2, 3, 
and 6 (a) when compared to untransduced cells (100%). Transduction efficiency after 72h in 
undifferentiated and differentiated MAPC measured by the percentage of cells expressing 
GFP vector (b). *p≤0.01, **p≤0.05, and #p=0.06, when statistically compared 
undifferentiated versus differentiated MAPC. Data are shown as mean ±SD of three 
independent experiments.
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Transduction efficiency and GFP expression on AAV6-transduced rMAPC after in vitro 
osteogenic differentiation. Number of GFP+ rMAPC cells after 3, 7 and 14 days of vector 
transfer at MOI 100 (a). GFP expression on untransduced differentiated MAPC (b), and on 
AAV6-GFP-transduced cells 4 days (c), 10 days (d), 14 days (e) after vector transfer at MOI 
100. Data are shown as mean ±SD of three independent experiments.
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Phenotypic and genotypic characterization of cell/matrices from 3D rMAPC cultures after 
38 days of osteogenic differentiation. Aggregate cultures supplemented with: osteogenic 
media (OM) with dexamethasone (a-b), OM without dexamethasone (c-d), and basal media 
without osteogenic supplements and without dexamethasone (e-f). Matrices were 
immunostained with collagen type I antibody (a,c,e) showing a immunoreactive matrix 
network (black arrows). Matrices (m) visualized under transmission electron microscopy 
(b,d,f) showing large mineralization areas with spindle-like and plate-like crystals (white 
arrows). mRNA expression of specific markers at the MAPC 3D aggregate differentiation 
(g-i). MAPC-specific markers (g), mesoderm-specific markers (h) and mid to late bone-
specific markers (i). Fold change was normalized to house-keeping genes and compared to 
baseline levels. Dexa: dexamethasone. **p<0.05 when statistically compared to both ΔCT at 
baseline and at OM day 38 of differentiation; *p<0.05 when statistically compared; #p<0.05 
when statistically compared to baseline level. Data are shown as mean ±SD of three 
independent experiments.
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β-catenin nuclear translocation (left) and p-GSK3 cellular localization (right) in rMAPC 
aggregate cultures in the presence and absence of dexamethasone in OM media after 38 days 
of osteogenic differentiation. Immunostained matrices from cultures with dexamethasone 
(a,c), and without dexamethasone (b,d). β-catenin immunoreactivity in red (a,b) and p-GSK3 
immunoreactivity in red (c,d). Blue: nuclear DAPI, Magnification: 400x.
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“In vivo” tracing of osteogenic-differentiated rMAPC cells after AAV6-GFP transduction in 
a calvaria bone CSD formation model. Macro-porous 3D hydroxyapatite-based scaffolds 
carried untransduced cells (a) or AAV6-GFP-transduced cells (b-e) and GFP expression was 
visualized by immunohistochemistry with anti-GFP antibody after 4 days (b) and 10 days (c) 
“in vivo” and with isotype IgG antibody after 4 (d) and 10 days (e). Sections were stained 
with DAB chromogen and counterstained with hematoxylin. Quantification of rMAPC-
GFP+ cells “in vivo” (f) by light microscopy counting, mean from 5 technical replicates. 
Hap: hydroxyapatite-based biomaterial. Nuclei counterstained with hematoxylin. 
Magnification: 100x.
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Expression of osteogenic markers and newly formed bone tissue 10 days after “in vivo” 
implantation of AAV6-GFP-transduced OD-rMAPCs in a calvaria bone regeneration CSD 
model. Osteogenically differentiated rMAPCs (OD-rMAPCs treated with dexamethasone) 
were either untransduced (a,d) or transduced with AAV6-GFP vector (b,c,e-i) and were 
loaded into macro-porous 3D hydroxyapatite-based scaffolds (Hap) before implantation. 
Expression of osteopontin (a,b) and osteocalcin (d,e) was visualized by 
immunohistochemistry with anti-osteopontin and anti-osteocalcin primary antibodies and 
with isotype IgG antibody for those markers respectively (c,f). Nuclei counterstained with 
Alcian blue (a-f). In Figures g-i: formation of bone-like matrix (bm), collagenous matrix (c) 
in the macro-porous areas, and formation of newly formed bone (nfb) at native bone-
scaffold interface can be visualized using hematoxylin-eosin (g) and Masson’s Trichrome 
(h-i) staining. These stains were used to assess bone-like and collagen matrix formation 
between the hydroxyapatite (Hap) biomaterials. bm: bone-like matrix; c: collagenous matrix; 
nfb: newly formed bone; nb: native bone; Magnification: 200x.
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Expression of the stem cell intracellular marker Oct4, 10 days after “in vivo” implantation of 
rMAPCs in a bone critical-size defect (CSD). Osteogenically differentiated rMAPCs (OD-
rMAPCs) transduced with AAV6-GFP vector (a,c) and untransduced (b,d) were loaded into 
hydroxyapatite-based scaffolds (Hap) before implantation. Expression of Oct4 (a, b) was 
visualized by immunohistochemistry with anti-Oct4 primary antibody and with isotype IgG 
antibody (c,d) plus DAB chromogen (brown staining). Nuclei counterstained with Alcian 
blue. Magnification: 200x.
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